Spring Series Webinar Bundle

Registration Information

By purchasing this discounted bundle, you will have access to attend all 3 of our 2024 Spring Series webinars. The links will be included in the confirmation email sent to you after your purchase. You may choose to attend the webinar at the date and time listed, or you can choose to watch the recording, which will be made available approximately one week after the live webinar date.  Each webinar recording will be posted to your dashboard a week after taking place, whether you attend it live or not. This allows learners the opportunity to re-watch the webinar(s) if they so choose.

You have until June 30th, 2024 to watch all webinars and claim credit. 

- Credit is awarded all in one certificate available as soon as all three webinars have take place. 

What's Included

Webinar 1 - Post-COVID Smokers

Tuesday, March 12, 2024 - 12:00 -1:00 pm CST

Presenter:  David D. McFadden, M.D.

Overview: 

Numerous reports in the medical literature have noted a “paradox of lower COVID prevalence and mortality among smokers”.  Is this a myth or fact?

We will explore the controversies surrounding the relationship between COVID and cigarette smoking.

Will also examine the pathogenesis of chronic lung disease among COVID + smokers and discuss briefly the frequency of COVID symptoms in COVID + vapers.

Goals & Objectives:

1. To clarify smoking related COVID risk and morbidity.
2. To identify possible chronic lung disorders related to COVID in smokers

Webinar 2 - Nicotine and ADHD: Understanding the Connection

Tuesday, April 16th, 2024 - 12:00 -1:00 pm CDT

Presenter:  Molly J. Leis, MS, LADC, LPCC, CTTS

Overview: ADHD is a brain disorder marked by an ongoing pattern of inattention, impulsivity and/or excessive activity, which interferes with functioning or development. Some people with ADHD only have problems with one of the behaviors, while others have a combination. An appealing short-term effect of nicotine is that it helps with the ability to focus. This is conceivably one reason why many people with ADHD use tobacco.  This webinar will look at the facts behind why there is a connection between nicotine and ADHD and how to most effectively treat those with ADHD who want to stop using tobacco products.   

Goals and Objectives: 

1. Identify Reasons People with ADHD May Use Nicotine at Higher Rates
2. Develop Effective Treatment Strategies for Nicotine Addiction and ADHD

Webinar 3 - How JUUL Reinvented the Electronic Cigarette

Tuesday, May 21, 2024 - 12:00 -1:00 pm CDT

Presenter: Richard D. Hurt, M.D.

Overview: Electronic cigarettes entered the United States tobacco market in the early part of the 21st century. The early e-cigarettes were modeled after the chemistry of conventional cigarettes and were not efficient nicotine delivery devices. The e-liquid used “free base” nicotine that had adversive side effects. In 2015, JUUL launched and “re-invented” the e-cigarette, by adding benzoic acid to nicotine, producing a salt nicotine. The company discovered that by reconfiguring the formula of the e-liquid, it produced equivalent blood nicotine levels as a conventional cigarette and thus had a similar addictive potential. This webinar will look at how the e-cigarette companies avoided FDA regulation, helping them to compete in the tobacco market. It will also look at how nicotine in different forms play a role in addiction.

Goals and Objectives: 

1. Explain basic pharmacology of nicotine, its 3 forms (diprotonated, mono protonated and unprotonated), and the effect of pH on the equilibrium and biologic availability of the forms.
2. Describe how conventional cigarettes are the most efficient nicotine delivery devices ever conceived, manufactured, and perfected.
3. Identify how JUUL scientists and managers enhanced the nicotine delivery of its vaping devices (utilizing knowledge about nicotine chemistry gleaned from previously secret tobacco industry documents) to emulate the delivery of conventional cigarettes and made the delivery of elevated levels of nicotine palatable.
4.  Explain how JUUL promoted its device as a method to help smokers “switch/stop” in the absence of randomized controled trials to prove safety and efficacy because it was more profitable to avoid regulation as a medical product.